SCHEMBL6630656

SCHEMBL6630656

CCCCOc1ccc(S(C)(=O)=O)cc1C(N)=O

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
S1PR3 Q99500 1/20 0.55
LMNA P02545 4/20 0.52
MEN1 O00255 2/20 0.52
KMT2A Q03164 2/20 0.52
ADRA2A P08913 2/20 0.52
HTR2B P41595 2/20 0.52
NR1I2 O75469 1/20 0.52
CHRM2 P08172 1/20 0.52
CYP3A4 P08684 1/20 0.52
MAPT P10636 1/20 0.52
OPRK1 P41145 1/20 0.52
SLC6A3 Q01959 1/20 0.52
HDAC6 Q9UBN7 1/20 0.52
MAPK1 P28482 1/20 0.49
RAB9A P51151 1/20 0.49
HTT P42858 1/20 0.46
TSHR P16473 2/20 0.44
CA12 O43570 2/20 0.44
CA1 P00915 2/20 0.44
CA2 P00918 2/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6630391 0.89 S1PR3 (0.52) S1PR3LMNAMEN1KMT2AADRA2A
SCHEMBL4130038 0.87 S1PR3 (0.71) S1PR3LMNAADRA2AHTR2BMAPK1
SCHEMBL21569260 0.87 LMNA (0.62) S1PR3LMNAMEN1KMT2AADRA2A
SCHEMBL6630509 0.85 S1PR3 (0.54) S1PR3LMNAMEN1KMT2AADRA2A
SCHEMBL4125056 0.83 S1PR3 (0.78) S1PR3LMNAMEN1KMT2AADRA2A
SCHEMBL6677588 0.81 LMNA (0.59) S1PR3LMNAMEN1KMT2AADRA2A
Iodide SCHEMBL6627950 0.81 S1PR3 (0.47) S1PR3LMNAMEN1KMT2AADRA2A
SCHEMBL22616413 0.81 LMNA (0.49) S1PR3LMNAMEN1KMT2AADRA2A
SCHEMBL7008034 0.80 S1PR3 (0.49) S1PR3LMNAMEN1KMT2AADRA2A
SCHEMBL6630953 0.80 S1PR3 (0.65) S1PR3LMNAADRA2AHTR2BMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1368352-B1 CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASE INHIBITORS PFIZER LTD (GB) 2004-12-01 EP disclosed
US-6770645-B2 SEXUAL DISORDERS THERAPY; ANTIALLERGENS; RESPIRATORY SYSTEM DISORDERS PFIZER INC. 2004-08-03 US disclosed
EP-1368352-A1 CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASE INHIBITORS Pfizer Limited (GB) 2003-12-10 EP disclosed
US-20030064990-A1 Pharmaceutically active compounds PFIZER INC. 2003-04-03 US disclosed
WO-2002074774-A1 CYCLIC GUANOSINE 3',5'-MONOPHOSPHATE PHOSPHODIESTERASE INHIBITORS PFIZER LIMITED (GB) 2002-09-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030064990-A1 Pharmaceutically active compounds PDE5A, PDE3A, PDE2A S1PR3 605/4885LMNA 2151/4885MEN1 1517/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.